Stock Events

Stock Events

Galmed Pharmaceuticals 

$0.69
0
+$0.01+0.86% Today

Statistics

Day High
0.8
Day Low
0.65
52W High
-
52W Low
-
Volume
8,907
Avg. Volume
-
Mkt Cap
3.78M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

1AprExpected
Q3 2025
Next
-0.54
-0.47
-0.4
-0.33
Expected EPS
-0.51
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
0Revenue
-15.03MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow GLMD.BOATS. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Madrigal Pharmaceuticals
MDGL
Mkt Cap9.34B
Madrigal Pharmaceuticals is developing treatments for NASH, directly competing with Galmed's pipeline.
Viking Therapeutics
VKTX
Mkt Cap4.3B
Viking Therapeutics is working on treatments for metabolic and endocrine disorders, including NASH, making it a direct competitor.
Genfit
GNFT
Mkt Cap211.72M
Genfit SA focuses on the discovery and development of drug candidates to treat liver diseases such as NASH, competing in the same space as Galmed.
Gilead Sciences
GILD
Mkt Cap148.78B
Gilead Sciences has a strong pipeline in liver disease treatments, including NASH, positioning it as a competitor.
Agios Pharmaceuticals
AGIO
Mkt Cap2.52B
Agios Pharmaceuticals, though primarily focused on cancer, has expanded into metabolic disorders, potentially competing in the NASH space.
Novartis
NVS
Mkt Cap237.61B
Novartis AG, a large pharmaceutical company, has interests in developing treatments for liver diseases, including NASH, making it a competitor.
Abbvie
ABBV
Mkt Cap385.18B
AbbVie Inc. has a diverse portfolio that includes research in liver diseases, potentially putting it in competition with Galmed.
Pfizer
PFE
Mkt Cap140.15B
Pfizer Inc. is involved in developing treatments for a wide range of conditions, including liver diseases, which could compete with Galmed's products.
Merck
MRK
Mkt Cap214.76B
Merck & Co., Inc. has a broad research portfolio that could include NASH treatments, positioning it as a potential competitor.

About

Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule which is in Phase III study for oral treatment for non-alcoholic steato-hepatitis (NASH) in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. Further, the company develops MyBiotics which is in pre-clinical trials for NASH and fibrosis. It has a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea; and a collaboration agreement with OnKai for its AI platform. Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Ramat Gan, Israel.
Show more...
CEO
Mr. Allen Baharaff
Employees
3
Country
IL
ISIN
IL0011313900

Listings

F
DE
GPH.F
XNAS
US
GLMD
BOATS
BOATS
GLMD.BOATS

0 Comments

Share your thoughts

FAQ

What is Galmed Pharmaceuticals stock price today?▼
The current price of GLMD.BOATS is $0.69 USD — it has increased by +0.86% in the past 24 hours. Watch Galmed Pharmaceuticals stock price performance more closely on the chart.
What is Galmed Pharmaceuticals stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Galmed Pharmaceuticals stocks are traded under the ticker GLMD.BOATS.
What is Galmed Pharmaceuticals market cap?▼
Today Galmed Pharmaceuticals has the market capitalization of 3.78M
When is the next Galmed Pharmaceuticals earnings date?▼
Galmed Pharmaceuticals is going to release the next earnings report on April 01, 2026.
What were Galmed Pharmaceuticals earnings last quarter?▼
GLMD.BOATS earnings for the last quarter are -0.33 USD per share, whereas the estimation was -0.54 USD resulting in a +38.89% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Galmed Pharmaceuticals revenue for the last year?▼
Galmed Pharmaceuticals revenue for the last year amounts to 0 USD.
What is Galmed Pharmaceuticals net income for the last year?▼
GLMD.BOATS net income for the last year is -15.03M USD.
How many employees does Galmed Pharmaceuticals have?▼
As of February 03, 2026, the company has 3 employees.
In which sector is Galmed Pharmaceuticals located?▼
Galmed Pharmaceuticals operates in the Health Care sector.
When did Galmed Pharmaceuticals complete a stock split?▼
Galmed Pharmaceuticals has not had any recent stock splits.
Where is Galmed Pharmaceuticals headquartered?▼
Galmed Pharmaceuticals is headquartered in Ramat Gan, IL.